The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

25 Nov 2016 11:32

RNS Number : 1935Q
Motif Bio PLC
25 November 2016
 
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Motif Bio plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

CHANGE IN NATURE : SHARES LOANED OUT &

CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PUBLIC OFFER

 

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

Available on Request 5,944*

 

BNY Norwich Union Nominees Limited 99,767* 

Chase (GA Group) Nominees Limited 3,801,750*

 

State Street Nominees Limited 1,038,396*

*denotes direct interest

 

Chase (GA Group) Nominees Limited 1,698,925

 

Chase Nominees Limited 329,800

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

23 November 2016

6. Date on which issuer notified:

24 November 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

 

4% to

>5% to

6% to 3% change at Direct Interest Level (Box 8A & 8B) and

>5% to

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

Ordinary Shares

 

GB00BVVT4H71

8,939,785*

8,939,785*

6,974,582

4,945,857

2,028,725

2.74%

1.12%

*Includes Right to Recall Loaned Shares (1,528,203)

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

 

1,965,203*

 

*Direct interest

1.09%

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

8,939,785

4.95%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited & Friends Provident International Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

Friends Provident International Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Life Holdings UK Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Friends Life FPG Limited (wholly owned subsidiary of Aviva Life Holdings UK Limited)

· Friends Life FPL Limited (wholly owned subsidiary of Friends Life FPG Limited)

· Friends Life Limited (wholly owned subsidiary of Friends Life FPL Limited)

· Friends Life and Pensions Limited (wholly owned subsidiary of Friends Life Limited)

· Friends Provident International Limited (wholly owned subsidiary of Friends Life and Pensions Limited)

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Figures are based on the total number of voting rights of 180,643,744 as per the Company's 'Closing of Public Offer' announcement of 23 November 2016.

 

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

01603 684420

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFFLLTLEFIR
Date   Source Headline
14th Sep 201611:15 amRNSIssue of Equity
8th Sep 20167:00 amRNSRe-negotiation of the terms of the CPNs
8th Sep 20167:00 amRNSUPDATE ON REVIVE-1 PHASE 3 CLINICAL TRIAL
26th Aug 20167:00 amRNSChief Medical Officer presents at congress in USA
22nd Aug 20164:31 pmRNSDirector/PDMR Shareholding
16th Aug 20167:00 amRNSHalf-year Report
9th Aug 20165:24 pmRNSHolding(s) in Company
9th Aug 20167:00 amRNSUpdate on timing of proposed US Public Offering
5th Aug 20167:00 amRNSHolding(s) in Company
1st Aug 20162:15 pmRNSResult of General Meeting
28th Jul 20164:22 pmRNSPreliminary prospectus filed
18th Jul 20164:38 pmRNSDirector/PDMR Shareholding
13th Jul 20167:01 amRNSCircular to allot shares for proposed US Offering
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSFiles For Proposed U.S. Public Offering
1st Jul 20167:00 amRNSDirectorate Change
2nd Jun 20163:37 pmRNSResult of AGM
1st Jun 20167:00 amRNSCEO to Present at BIO 2016
24th May 20167:00 amRNSInvestor presentation
28th Apr 20167:03 amRNSRe. Amphion Innovations plc
25th Apr 20167:00 amRNSReplay for Analyst & Investor Conference Call
22nd Apr 20167:00 amRNSGrant of Options
21st Apr 20167:00 amRNSAnnual Report and Accounts 2015
20th Apr 20167:00 amRNSFinal Results
18th Apr 20167:00 amRNSResults Conference Call Details
14th Apr 20167:00 amRNSSenior Appointments
23rd Mar 20167:00 amRNSMotif Bio to present at BIO-Europe Spring
14th Mar 20167:00 amRNSAppointment of strategic adviser
2nd Mar 20167:00 amRNSFirst patient dosed in iclaprim Phase 3 trials
23rd Feb 20165:39 pmRNSHolding(s) in Company
22nd Feb 20167:00 amRNSWebcast on Combating antibiotic resistance
25th Jan 20167:00 amRNSAppointments of U.S. finance adviser and auditor
22nd Dec 20157:00 amRNSExercise of Warrants
15th Dec 20157:00 amRNSIclaprim Clinical Trial Supplies Manufactured
7th Dec 20157:00 amRNSMotif selected to present at Biotech Showcase
24th Nov 20157:00 amRNSReceipt of FDA Concurrence
11th Nov 20157:00 amRNSEuropean Agreement for Iclaprim Development
27th Oct 20157:00 amRNSSelected to Present at BIO-Europe 2015
21st Oct 20157:00 amRNSExercise of Options
16th Oct 20157:00 amRNSLeading CRO to Conduct Iclaprim Phase III Trials
13th Oct 20157:00 amRNSResults of Two Posters on Iclaprim at ID Week 2015
12th Oct 20153:59 pmRNSExercise of Options
5th Oct 20154:41 pmRNSDirectors Dealings
29th Sep 20157:01 amRNSPresentation of Two Posters on Iclaprim
23rd Sep 20153:04 pmRNSIssue of Shares for Exercised Warrants
3rd Sep 20157:00 amRNSFDA Grants Fast Track Designation for Iclaprim
2nd Sep 20157:00 amRNSAppointment of IR Adviser
2nd Sep 20157:00 amRNSParticipation at Upcoming Investor Events
27th Aug 20157:01 amRNSInterims Results for the 6 months to 30 June 2015
24th Aug 20157:00 amRNSPotent Efficacy of Iclaprim Confirmed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.